Switch to:
Also traded in: Austria, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.23
XRAY's Cash-to-Debt is ranked lower than
84% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. XRAY: 0.23 )
Ranked among companies with meaningful Cash-to-Debt only.
XRAY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.08 Max: No Debt
Current: 0.23
Equity-to-Asset 0.70
XRAY's Equity-to-Asset is ranked higher than
70% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. XRAY: 0.70 )
Ranked among companies with meaningful Equity-to-Asset only.
XRAY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.52 Max: 0.8
Current: 0.7
0.22
0.8
Interest Coverage 12.95
XRAY's Interest Coverage is ranked lower than
68% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.06 vs. XRAY: 12.95 )
Ranked among companies with meaningful Interest Coverage only.
XRAY' s Interest Coverage Range Over the Past 10 Years
Min: 6.71  Med: 10.6 Max: 17.41
Current: 12.95
6.71
17.41
Piotroski F-Score: 5
Altman Z-Score: 3.58
Beneish M-Score: -2.61
WACC vs ROIC
10.20%
4.05%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 12.04
XRAY's Operating Margin % is ranked higher than
70% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. XRAY: 12.04 )
Ranked among companies with meaningful Operating Margin % only.
XRAY' s Operating Margin % Range Over the Past 10 Years
Min: 11.85  Med: 14.73 Max: 17.66
Current: 12.04
11.85
17.66
Net Margin % 9.42
XRAY's Net Margin % is ranked higher than
76% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. XRAY: 9.42 )
Ranked among companies with meaningful Net Margin % only.
XRAY' s Net Margin % Range Over the Past 10 Years
Min: 9.39  Med: 11.27 Max: 12.94
Current: 9.42
9.39
12.94
ROE % 4.41
XRAY's ROE % is ranked higher than
53% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. XRAY: 4.41 )
Ranked among companies with meaningful ROE % only.
XRAY' s ROE % Range Over the Past 10 Years
Min: 4.41  Med: 13.89 Max: 18.61
Current: 4.41
4.41
18.61
ROA % 3.13
XRAY's ROA % is ranked higher than
59% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. XRAY: 3.13 )
Ranked among companies with meaningful ROA % only.
XRAY' s ROA % Range Over the Past 10 Years
Min: 3.13  Med: 6.55 Max: 10.69
Current: 3.13
3.13
10.69
ROC (Joel Greenblatt) % 32.27
XRAY's ROC (Joel Greenblatt) % is ranked higher than
78% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. XRAY: 32.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
XRAY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 31.15  Med: 38.16 Max: 54.55
Current: 32.27
31.15
54.55
3-Year Revenue Growth Rate -6.00
XRAY's 3-Year Revenue Growth Rate is ranked lower than
76% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. XRAY: -6.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
XRAY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6  Med: 11.9 Max: 42.9
Current: -6
-6
42.9
3-Year EBITDA Growth Rate -3.60
XRAY's 3-Year EBITDA Growth Rate is ranked lower than
71% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. XRAY: -3.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
XRAY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -22.4  Med: 9.5 Max: 50.5
Current: -3.6
-22.4
50.5
3-Year EPS without NRI Growth Rate -3.50
XRAY's 3-Year EPS without NRI Growth Rate is ranked lower than
64% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. XRAY: -3.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
XRAY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -32.9  Med: 11 Max: 88.3
Current: -3.5
-32.9
88.3
GuruFocus has detected 5 Warning Signs with Dentsply Sirona Inc $XRAY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» XRAY's 30-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

XRAY Guru Trades in Q2 2016

Jim Simons 182,658 sh (New)
Ray Dalio 6,000 sh (New)
Chuck Royce 66,000 sh (+17.86%)
Vanguard Health Care Fund 1,904,590 sh (unchged)
Joel Greenblatt Sold Out
Ruane Cunniff 4,705,249 sh (-2.85%)
Mario Gabelli 126,210 sh (-3.37%)
Columbia Wanger 768,298 sh (-13.72%)
Paul Tudor Jones 4,500 sh (-38.36%)
» More
Q3 2016

XRAY Guru Trades in Q3 2016

Andreas Halvorsen 694,607 sh (New)
Paul Tudor Jones 8,243 sh (+83.18%)
Ruane Cunniff 8,163,402 sh (+73.50%)
Chuck Royce 69,000 sh (+4.55%)
Vanguard Health Care Fund 1,904,590 sh (unchged)
Mario Gabelli 125,310 sh (-0.71%)
Jim Simons 180,458 sh (-1.20%)
Columbia Wanger 614,039 sh (-20.08%)
Ray Dalio 4,500 sh (-25.00%)
» More
Q4 2016

XRAY Guru Trades in Q4 2016

Pioneer Investments 877,100 sh (New)
Andreas Halvorsen 1,680,154 sh (+141.89%)
Jim Simons 301,858 sh (+67.27%)
Ruane Cunniff 9,102,714 sh (+11.51%)
Chuck Royce 75,900 sh (+10.00%)
Vanguard Health Care Fund 1,904,590 sh (unchged)
Ray Dalio Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli 121,210 sh (-3.27%)
Columbia Wanger 516,159 sh (-15.94%)
» More
Q1 2017

XRAY Guru Trades in Q1 2017

Steven Cohen 1,027,933 sh (New)
Jim Simons 1,044,558 sh (+246.04%)
Chuck Royce 102,650 sh (+35.24%)
Pioneer Investments 884,680 sh (+0.86%)
Vanguard Health Care Fund 1,904,590 sh (unchged)
Ruane Cunniff 8,721,237 sh (-4.19%)
Mario Gabelli 114,210 sh (-5.78%)
Columbia Wanger 458,186 sh (-11.23%)
Andreas Halvorsen 854,398 sh (-49.15%)
» More
» Details

Insider Trades

Latest Guru Trades with XRAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339114    SIC: 3843
Compare:OTCPK:TRUMY, NYSE:WAT, NYSE:MTD, OTCPK:OCPNY, NAS:HOLX, OTCPK:CLPBY, NYSE:COO, NYSE:RMD, OTCPK:SAUHY, NYSE:WST, NYSE:STE, NYSE:BCR, OTCPK:GNGBF, NYSE:HRC, NAS:ICUI, NYSE:CMD, OTCPK:ANSLY, NAS:PODD, NAS:ILMN, NYSE:HAE » details
Traded in other countries:XRAY.Austria, DY2.Germany,
Headquarter Location:USA
Dentsply Sirona Inc is a designer, developer, manufacturer and marketer of consumable dental products for the professional dental market. The Company also manufactures and markets other consumable medical device products.

Dentsply Sirona is one of the world's largest manufacturers and distributors of dental supplies and equipment. Its product segments include dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. Over half of its products are sold through dental distributors, and approximately 65% of Dentsply's sales are outside the U.S.

Guru Investment Theses on Dentsply Sirona Inc

Ruane Cunniff Comments on Dentsply Sirona - Oct 13, 2016

After a busy second quarter in terms of portfolio activity, the third quarter was far quieter. Our only significant purchase was of the dental supply leader Dentsply Sirona (NASDAQ:XRAY). We’ve owned predecessor company Sirona since 2011, and it has been an excellent performer. Our original investment thesis was based on Sirona’s leadership in digital dentistry. Sirona is strong in digital equipment, and its product line includes CEREC, an incredibly innovative and useful CAD/CAM system that allows dentists to design and mill crowns in their offices during the course of a single patient visit. The merger brings together the highest-tech maker of dental equipment (Sirona) with the largest maker of dental consumables (Dentsply), creating the industry’s largest global supplier. It is our belief that Dentsply Sirona is in a unique position to create and sell new value-added solutions in both equipment and consumables over the years ahead. In addition, we think CEO Jeff Slovin is the right person to drive the combined organization toward a world-class level of performance.

From Ruane Cunniff (Trades, Portfolio)'s Sequoia Fund third quarter 2016 letter to shareholders.

Check out Ruane Cunniff latest stock trades

Top Ranked Articles about Dentsply Sirona Inc

Dentsply Sirona to Report First Quarter 2017 Results on May 9
Ruane Cunniff Makes One Significant Buy Sequoia Fund enters dental space after disposing of Valeant
On Tuesday, Ruane Cunniff (Trades, Portfolio) disclosed its first quarterly update since losing significantly on a position in Valeant Pharmaceuticals (NYSE:VRX), a fast-growing drug maker accused of price gouging and a dubious relationship with a pharmacy. The firm’s Sequoia Fund made only one large purchase during the third quarter, Dentsply Sirona (NASDAQ:XRAY). Read more...
Ruane Cunniff Comments on Dentsply Sirona Guru stock highlight
After a busy second quarter in terms of portfolio activity, the third quarter was far quieter. Our only significant purchase was of the dental supply leader Dentsply Sirona (NASDAQ:XRAY). We’ve owned predecessor company Sirona since 2011, and it has been an excellent performer. Our original investment thesis was based on Sirona’s leadership in digital dentistry. Sirona is strong in digital equipment, and its product line includes CEREC, an incredibly innovative and useful CAD/CAM system that allows dentists to design and mill crowns in their offices during the course of a single patient visit. The merger brings together the highest-tech maker of dental equipment (Sirona) with the largest maker of dental consumables (Dentsply), creating the industry’s largest global supplier. It is our belief that Dentsply Sirona is in a unique position to create and sell new value-added solutions in both equipment and consumables over the years ahead. In addition, we think CEO Jeff Slovin is the right person to drive the combined organization toward a world-class level of Read more...
Ruane Cunniff Acquires Shares of Dentsply Sirona Company makes and sells products for dental market
Ruane Cunniff (Trades, Portfolio) bought a 4,843,324-share stake in Dentsply Sirona Inc. (NASDAQ:XRAY) during the first quarter. Read more...

Ratios

vs
industry
vs
history
PE Ratio 40.47
XRAY's PE Ratio is ranked higher than
51% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.48 vs. XRAY: 40.47 )
Ranked among companies with meaningful PE Ratio only.
XRAY' s PE Ratio Range Over the Past 10 Years
Min: 12.2  Med: 21.94 Max: 114
Current: 40.47
12.2
114
Forward PE Ratio 22.17
XRAY's Forward PE Ratio is ranked higher than
63% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.42 vs. XRAY: 22.17 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 40.47
XRAY's PE Ratio without NRI is ranked higher than
50% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.38 vs. XRAY: 40.47 )
Ranked among companies with meaningful PE Ratio without NRI only.
XRAY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.2  Med: 21.94 Max: 114
Current: 40.47
12.2
114
Price-to-Owner-Earnings 27.22
XRAY's Price-to-Owner-Earnings is ranked higher than
50% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.93 vs. XRAY: 27.22 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
XRAY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.21  Med: 20.23 Max: 104.95
Current: 27.22
12.21
104.95
PB Ratio 1.78
XRAY's PB Ratio is ranked higher than
73% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. XRAY: 1.78 )
Ranked among companies with meaningful PB Ratio only.
XRAY' s PB Ratio Range Over the Past 10 Years
Min: 1.58  Med: 2.73 Max: 4.65
Current: 1.78
1.58
4.65
PS Ratio 3.81
XRAY's PS Ratio is ranked lower than
55% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. XRAY: 3.81 )
Ranked among companies with meaningful PS Ratio only.
XRAY' s PS Ratio Range Over the Past 10 Years
Min: 1.58  Med: 2.41 Max: 3.99
Current: 3.81
1.58
3.99
Price-to-Free-Cash-Flow 29.36
XRAY's Price-to-Free-Cash-Flow is ranked lower than
59% of the 73 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.88 vs. XRAY: 29.36 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
XRAY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.38  Med: 19.74 Max: 34.39
Current: 29.36
12.38
34.39
Price-to-Operating-Cash-Flow 22.90
XRAY's Price-to-Operating-Cash-Flow is ranked lower than
64% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.90 vs. XRAY: 22.90 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
XRAY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.42  Med: 15.35 Max: 26.51
Current: 22.9
10.42
26.51
EV-to-EBIT 32.05
XRAY's EV-to-EBIT is ranked lower than
77% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.30 vs. XRAY: 32.05 )
Ranked among companies with meaningful EV-to-EBIT only.
XRAY' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.6  Med: 18.8 Max: 59.5
Current: 32.05
9.6
59.5
EV-to-EBITDA 19.76
XRAY's EV-to-EBITDA is ranked lower than
65% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.15 vs. XRAY: 19.76 )
Ranked among companies with meaningful EV-to-EBITDA only.
XRAY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.4  Med: 14.7 Max: 39.7
Current: 19.76
8.4
39.7
PEG Ratio 11.63
XRAY's PEG Ratio is ranked lower than
91% of the 58 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.65 vs. XRAY: 11.63 )
Ranked among companies with meaningful PEG Ratio only.
XRAY' s PEG Ratio Range Over the Past 10 Years
Min: 0.65  Med: 3.78 Max: 35.86
Current: 11.63
0.65
35.86
Shiller PE Ratio 30.57
XRAY's Shiller PE Ratio is ranked higher than
73% of the 45 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 43.41 vs. XRAY: 30.57 )
Ranked among companies with meaningful Shiller PE Ratio only.
XRAY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.1  Med: 25.69 Max: 44.86
Current: 30.57
18.1
44.86
Current Ratio 2.30
XRAY's Current Ratio is ranked lower than
51% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. XRAY: 2.30 )
Ranked among companies with meaningful Current Ratio only.
XRAY' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 1.88 Max: 4.36
Current: 2.3
1.2
4.36
Quick Ratio 1.55
XRAY's Quick Ratio is ranked higher than
53% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. XRAY: 1.55 )
Ranked among companies with meaningful Quick Ratio only.
XRAY' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 1.06 Max: 2.98
Current: 1.55
0.63
2.98
Days Inventory 110.51
XRAY's Days Inventory is ranked higher than
62% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. XRAY: 110.51 )
Ranked among companies with meaningful Days Inventory only.
XRAY' s Days Inventory Range Over the Past 10 Years
Min: 89.71  Med: 101.08 Max: 114.74
Current: 110.51
89.71
114.74
Days Sales Outstanding 56.41
XRAY's Days Sales Outstanding is ranked higher than
50% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.76 vs. XRAY: 56.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
XRAY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.12  Med: 56.27 Max: 61.98
Current: 56.41
53.12
61.98
Days Payable 52.42
XRAY's Days Payable is ranked lower than
54% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.53 vs. XRAY: 52.42 )
Ranked among companies with meaningful Days Payable only.
XRAY' s Days Payable Range Over the Past 10 Years
Min: 31.01  Med: 37.45 Max: 52.42
Current: 52.42
31.01
52.42

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.51
XRAY's Dividend Yield % is ranked lower than
84% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. XRAY: 0.51 )
Ranked among companies with meaningful Dividend Yield % only.
XRAY' s Dividend Yield % Range Over the Past 10 Years
Min: 0.35  Med: 0.54 Max: 0.85
Current: 0.51
0.35
0.85
Dividend Payout Ratio 0.21
XRAY's Dividend Payout Ratio is ranked higher than
75% of the 85 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.30 vs. XRAY: 0.21 )
Ranked among companies with meaningful Dividend Payout Ratio only.
XRAY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.1  Med: 0.11 Max: 0.21
Current: 0.21
0.1
0.21
3-Year Dividend Growth Rate 7.40
XRAY's 3-Year Dividend Growth Rate is ranked lower than
59% of the 64 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.60 vs. XRAY: 7.40 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
XRAY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 6.6 Max: 37.5
Current: 7.4
0
37.5
Forward Dividend Yield % 0.55
XRAY's Forward Dividend Yield % is ranked lower than
87% of the 143 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.35 vs. XRAY: 0.55 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.78
XRAY's 5-Year Yield-on-Cost % is ranked lower than
77% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.87 vs. XRAY: 0.78 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
XRAY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.53  Med: 0.82 Max: 1.3
Current: 0.78
0.53
1.3
3-Year Average Share Buyback Ratio -17.40
XRAY's 3-Year Average Share Buyback Ratio is ranked lower than
81% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.20 vs. XRAY: -17.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
XRAY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -67.6  Med: 0.3 Max: 2.2
Current: -17.4
-67.6
2.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.46
XRAY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
73% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.03 vs. XRAY: 1.46 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
XRAY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.99  Med: 1.49 Max: 7.53
Current: 1.46
0.99
7.53
Price-to-Median-PS-Value 1.58
XRAY's Price-to-Median-PS-Value is ranked lower than
71% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. XRAY: 1.58 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
XRAY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36  Med: 0.87 Max: 1.6
Current: 1.58
0.36
1.6
Earnings Yield (Greenblatt) % 3.13
XRAY's Earnings Yield (Greenblatt) % is ranked lower than
52% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. XRAY: 3.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
XRAY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.7  Med: 5.3 Max: 10.4
Current: 3.13
1.7
10.4
Forward Rate of Return (Yacktman) % 4.88
XRAY's Forward Rate of Return (Yacktman) % is ranked lower than
63% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. XRAY: 4.88 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
XRAY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -3.5  Med: 9.7 Max: 31.1
Current: 4.88
-3.5
31.1

More Statistics

Revenue (TTM) (Mil) $3,873
EPS (TTM) $ 1.55
Beta1.45
Short Percentage of Float2.82%
52-Week Range $55.00 - 65.83
Shares Outstanding (Mil)229.23

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 4,037 4,231 4,375
EPS ($) 2.86 3.20 3.33
EPS without NRI ($) 2.86 3.20 3.33
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.75%
Dividends per Share ($) 0.32 0.32 0.39
» More Articles for XRAY

Headlines

Articles On GuruFocus.com
Dentsply Sirona Expected to Leap in EPS May 08 2017 
Dentsply Sirona to Report First Quarter 2017 Results on May 9 May 03 2017 
Ruane Cunniff Makes One Significant Buy Oct 14 2016 
Ruane Cunniff Comments on Dentsply Sirona Oct 13 2016 
Sequoia Fund 3rd Quarter Update, Wells Fargo an 'Attractive Franchise' Oct 13 2016 
Ruane Cunniff Acquires Shares of Dentsply Sirona Jun 23 2016 
DENTSPLY´s Growth Opportunities Dec 16 2014 
Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY Dec 08 2014 
Why I Like These Two Health Care Stocks Aug 29 2014 
Global for Resilience – Columbia Management Selling Update Aug 29 2013 

More From Other Websites
DENTSPLY SIRONA, Inc. breached its 50 day moving average in a Bullish Manner : XRAY-US : May 24,... May 24 2017
What Analysts Recommend for Dentsply Sirona after Its 1Q17 May 16 2017
A Look at Dentsply Sirona’s 2017 Guidance May 15 2017
How Dentsply Sirona’s Profitability Metrics Looked in 1Q17 May 15 2017
Dentsply Sirona’s New Growth Strategy to Accelerate Digital Dentistry Penetration May 15 2017
Edited Transcript of XRAY earnings conference call or presentation 9-May-17 12:30pm GMT May 15 2017
What Dragged Down Technology Business Sales in 1Q17? May 12 2017
DENTSPLY SIRONA, Inc. – Value Analysis (NASDAQ:XRAY) : May 12, 2017 May 12 2017
Dentsply Sirona’s Dental and Heathcare Consumables Segment Growth Led by Europe May 12 2017
Dentsply Sirona’s 1Q17 Results Missed Analysts’ Estimates May 12 2017
DENTSPLY SIRONA, Inc. breached its 50 day moving average in a Bearish Manner : XRAY-US : May 11,... May 11 2017
DENTSPLY (XRAY) Earnings and Revenues Miss Estimates in Q1 May 09 2017
Investor Network: DENTSPLY SIRONA, Inc. to Host Earnings Call May 09 2017
DENTSPLY (XRAY) Q1 Earnings Miss Estimates, Sales Up Y/Y May 09 2017
Dentsply misses Street 1Q forecasts May 09 2017
Dentsply Sirona Reports First Quarter 2017 Results May 09 2017
Dentsply Sirona Expected to Leap in EPS May 08 2017
Medical Product Q1 Earnings Due on May 9: XRAY, HSIC & More May 08 2017
Dentsply Sirona’s Earnings Estimates: Must-Knows for 1Q17 May 05 2017
Will Dentsply Sirona Beat Analysts’ Revenue Estimates in 1Q17? May 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}